Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Core Viewpoint - Larimar Therapeutics, Inc. is set to host a conference call and webcast on June 23, 2025, to discuss regulatory updates regarding its nomlabofusp clinical development program for Friedreich's Ataxia [1] Company Overview - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases [3] - The company's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's Ataxia [3] - Larimar plans to utilize its intracellular delivery platform to design additional fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds [3] Conference Call and Webcast Details - The conference call and webcast will take place on June 23, 2025, at 8:00 am EDT [2] - Participants can access the event via a provided link or by phone using specific domestic and international numbers [2] - An archived version of the webcast will be available on the Larimar website following the live event [2]